<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02193594</url>
  </required_header>
  <id_info>
    <org_study_id>CRADLE</org_study_id>
    <nct_id>NCT02193594</nct_id>
  </id_info>
  <brief_title>Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma</brief_title>
  <official_title>Phase Ⅱ/Ⅲ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preoperative chemoradiotherapy(CRT) had been introduced in the comprehensive treatment of
      gastroesophageal junction and upper gastric cancers in the decade.According to some
      researches,CRT had shown its good curative effects in local control and prolonged overall
      survival.However,the optimization scheme for CRT and its influence to surgery remains
      controversial.Meanwhile,there were many design flaws in the past few research,such as the
      lack of adjuvant chemotherapy,the insufficiency in lymphnodes dissection.We decided to carry
      out the trial,eliminating all the bias as far as we can,to illustrate the efficacy and safety
      of CRT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The patient's survival time and recurrence time</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>3-year overall survival
1-year and 3-year recurrence free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients with complications</measure>
    <time_frame>Within 30 days after the day of operation</time_frame>
    <description>the morbidity and mortality rates within 30 days after the day of operation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The pathologic profiles and the pathologic response rates</measure>
    <time_frame>Within 30 days after the day of operation</time_frame>
    <description>the pathologic profiles and the pathologic response rates</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>CCRT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient in CCRT group will receive the preoperative concurrent chemoradiotherapy for 5 weeks and sequential radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient in CT group will receive radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Preoperative concurrent chemoradiotherapy</intervention_name>
    <description>The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.</description>
    <arm_group_label>CCRT group</arm_group_label>
    <other_name>CCRT</other_name>
    <other_name>Eloxatin®</other_name>
    <other_name>S-1®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical D2 total gastrectomy</intervention_name>
    <description>Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.</description>
    <arm_group_label>CCRT group</arm_group_label>
    <arm_group_label>CT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy</intervention_name>
    <description>Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA＜1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA＞1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.</description>
    <arm_group_label>CCRT group</arm_group_label>
    <arm_group_label>CT group</arm_group_label>
    <other_name>Eloxatin®</other_name>
    <other_name>S-1®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the gastroesophageal junction.

          -  Clinical stage diagnosed by endoscopic ultrasound(EUS) or computed tomography(CT) as
             T3-4NxM0 tumors,according to American Joint Committee on Cancer (AJCC) 7th edition.

          -  Eastern Cooperative Oncology Group (ECOG) performance status≤2.

          -  Informed consent obtained.

        Exclusion Criteria:

          -  Combined with other malignant tumors.

          -  Eastern Cooperative Oncology Group (ECOG) performance status＞2.

          -  Combined with severe organ dysfunction.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiafu Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiafu Ji, M.D.</last_name>
    <email>jiafuj@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Haidian District</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuangxi Li, M.D.</last_name>
      <email>lishuangxi@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Jiafu Ji, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ziyu Li, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuangxi Li, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2014</study_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jiafu Ji</investigator_full_name>
    <investigator_title>President of Beijing Cancer Hospital,Director of Key Laboratory of Carcinogenesis and Translational Research(Gastric Cancer Laboratory)</investigator_title>
  </responsible_party>
  <keyword>Preoperative concurrent chemoradiotherapy</keyword>
  <keyword>Neoadjuvant chemoradiotherapy</keyword>
  <keyword>Gastroesophageal junction adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

